Original articlePatient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France
Introduction
Chronic hepatitis C (HCV) is a growing public health concern, with up to 3% of the population infected and an estimated 360,000 HCV-related deaths each year, worldwide [1]. Within the World Health Organization (WHO) European region, approximately nine million people are chronically infected with HCV [2]. In France, HCV prevalence is estimated at 0.84% (approximately 550,000 citizens) [3], and HCV is responsible for approximately 11.5 deaths per 100,000 residents annually [4]. HCV disease progression can occur over a 20–50-year period [5]; long-term sequelae of chronic infection may include cirrhosis, liver decompensation, hepatocellular carcinoma (HCC), and the need for liver transplantation [6], [7]. In France, cases of cirrhosis and its complications are increasing and are predicted to peak in 2021 [8].
HCV infection causes fatigue, muscle and joint pain, depression, and other psychological disorders, which reduce patient health-related quality of life (HRQoL) and health utility [9], [10]. The decrements in health utility have been linked to severity of liver disease, with the lowest scores seen in patients with decompensated cirrhosis or HCC [9], [11], [12], [13]. HCV treatment is also associated with decreased HRQoL [14]. Despite some advances in the treatment of HCV, interferon (IFN) is still a component of therapy. Administration of current IFN-containing regimens for treatment of chronic HCV infection is challenging due to side effects such as anaemia, depression, flu-like symptoms, neuropsychiatric disorders, neutropenia, and rash, which negatively impact HRQoL and health utility of patients on treatment [15], [16], [17]. Sustained virologic response (SVR) with IFN-based therapy may result in improvements in HRQoL and health utility after treatment is completed [17], [18].
Direct costs associated with HCV are substantial [19]. Additionally, indirect economic and humanistic costs are significant and arise from the reduction of HRQoL owing to both the disease and current HCV treatments; this impacts patient work, daily activities, and lifestyle [15], [20], [21].
To fully characterize the impact of HCV and the burden of disease progression, the negative effects of HCV on worker productivity and patients’ lifestyle need to be understood. In France, there is a lack of studies quantifying HCV patient health utility, worker productivity decrement, and lifestyle impairment. Such data can be used to identify the real costs and benefits of treating HCV patients and preventing disease progression, and are important for accurately capturing the true burden of HCV disease. This information will help define future economic implications associated with HCV and inform public health strategy in France.
The primary objectives of this study were to evaluate HCV patient-reported health utility, defined as a measure of a patient's preference for a specific level of health status, and worker productivity (absenteeism, presenteeism, overall work productivity and activity impairment) in France by disease stage and treatment status. The secondary objectives were to determine the characteristics associated with lower health utility and reduced productivity among HCV patients in France and understand the effects of HCV on lifestyle.
Section snippets
Data collection
Data were obtained from the Adelphi Real World Hepatitis C Disease Specific Programme® (DSP) in France. This was part of a cross-sectional, multi-sponsor survey developed to collect marketing and health outcomes information from the United States and 5 European markets (France, Germany, Italy, Spain and the United Kingdom). The study was run according to EphMRA Market Research Guidelines. Ethical approval was not necessary; however, patient consent to take part was required as information was
Results
Sixty physicians were recruited in France. PRFs were completed for 597 patients. Of these, 297 completed corresponding PSC forms. These were included in the final analysis. Of the 60 physicians participating in the study, 13 (21.7%) described themselves as hepatologists, 25 (41.7%) as gastroenterologists, 13 (21.7%) as infectious disease specialists, and 9 (15.0%) as hepatogastroenterologists. The majority of physicians had a hospital practice (66.7%), while 5 (8.3%) had an office practice, and
Discussion
Patients with HCV report reduced HRQoL in comparison to the general population [9], [10]. This information is necessary to understand the true costs and benefits of treating patients and preventing disease progression, as innovative and highly effective treatments may alleviate HCV-related work impairment, lower the use of healthcare resources, and provide improved HRQoL to infected individuals [21].
This study used a cross-sectional survey of HCV patients in France to quantify patient health
Disclosure of interest
Jennifer C. Samp and Robert W. Baran are AbbVie employees and may hold AbbVie stock or options.
Richard Perry, James Piercy, and Robert Wood are employees of Adelphi Real World and served as consultants to AbbVie.
Funding: The design, analysis, and financial support of this study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the presentation. The data from the Hepatitis C Disease Specific Programme® were sourced from a multi-sponsored survey
Acknowledgements
Jane Kondejewski of SNELL Medical Communication Inc. provided assistance in the writing and preparation of this manuscript; this support was funded by AbbVie. The authors retained full editorial control of the manuscript content.
References (27)
- et al.
Health-state utilities and quality of life in hepatitis C patients
Am J Gastroenterol
(2003) - et al.
Health-related quality of life in chronic liver disease: the impact of type and severity of disease
Am J Gastroenterol
(2001) The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity
J Hepatol
(2001)Hepatitis C fact sheet No. 164. Revised 2013
(2013)- et al.
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference
J Viral Hep
(2011) - et al.
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors
J Med Virol
(2010) - et al.
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
BMC Public Health
(2009) - et al.
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
Health Technol Assess
(2007) Natural history of chronic hepatitis C
Hepatology
(2002)- et al.
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma
Liver Transpl
(2012)
Predicted effects of treatment for HCV infection vary among European countries
Gastroenterology
Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy
J Clin Gastroenterol
Determinants of quality of life in chronic liver patients
Aliment Pharmacol Ther
Cited by (9)
HepaDisk – A new quality of life questionnaire for HCV patients
2019, Digestive and Liver DiseaseCitation Excerpt :Indeed, hepatitis C, now considered a disease that affects the whole body and not just the liver, is associated with marked psychiatric morbidity and social impairment, characterized by anxiety, depression, social withdrawal, significant reduction of the quality of life (QoL), feelings of stigmatization, and loss of productivity [1–8]. To date, several validated instruments to assess the clinical severity of hepatitis C are available, while only a few specific instruments assessing the impact on QoL and working capability of liver disease have been developed and validated [9–14]. Moreover, the impact of HCV infection on patient QoL is rarely, if ever, assessed outside specialized centers [15,16].
DEPRESSION, ANXIETY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION IN VOJVODINA
2021, Acta Clinica CroaticaHepatitis C in the Brazilian public health care system: Burden of disease
2018, Arquivos de Gastroenterologia